Biocryst Pharmaceuticals (BCRX) Receivables - Net (2023 - 2025)
Biocryst Pharmaceuticals (BCRX) has disclosed Receivables - Net for 9 consecutive years, with $106.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 35.09% year-over-year to $106.8 million, compared with a TTM value of $106.8 million through Dec 2025, up 35.09%, and an annual FY2025 reading of $106.8 million, up 35.09% over the prior year.
- Receivables - Net was $106.8 million for Q4 2025 at Biocryst Pharmaceuticals, up from $91.3 million in the prior quarter.
- Across five years, Receivables - Net topped out at $106.8 million in Q4 2025 and bottomed at $2.1 million in Q2 2023.
- Average Receivables - Net over 3 years is $58.4 million, with a median of $64.7 million recorded in 2023.
- The sharpest move saw Receivables - Net plummeted 92.64% in 2024, then surged 4202.83% in 2025.
- Year by year, Receivables - Net stood at $57.0 million in 2023, then soared by 38.84% to $79.1 million in 2024, then surged by 35.09% to $106.8 million in 2025.
- Business Quant data shows Receivables - Net for BCRX at $106.8 million in Q4 2025, $91.3 million in Q3 2025, and $91.2 million in Q2 2025.